Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Galapagos : increases share capital through subscription right exercises (Form 6-K)

06/08/2021 | 06:17am EDT

Galapagos increases share capital through subscription right exercises

Mechelen, Belgium; 7 June 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

Galapagos issued 10,940 new ordinary shares on 7 June 2021, for a total capital increase (including issuance premium) of €325,279.

Pursuant to the subscription right exercise program of Galapagos' management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, one management board member exercised 5,000 subscription rights.

In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €354,418,623.11, the total number of securities conferring voting rights amounts to 65,522,521, which is also the total number of voting rights (the 'denominator'), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (formerly known as warrants) to subscribe to not yet issued securities conferring voting rights is (i) 6,709,662 subscription rights under several outstanding employee subscription right plans, which equals 6,709,662 voting rights that may result from the exercise of those subscription rights, and (ii) one subscription right issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead and its affiliates to 29.9% of the actually issued and outstanding shares after the exercise of the subscription right. This excludes the 2,736,250 subscription rights of Subscription Right Plan 2021 BE, Subscription Right Plan 2021 RMV and Subscription Right Plan 2021 ROW, which were created subject to acceptance. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.


Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+1 781 296 1143

Carmen Vroonen
Global Head of Communications & Public Affairs
+32 473 824 874

Kyra Obolensky
Senior Director Corporate Communications
+32 491 92 64 35

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.


Galapagos NV published this content on 08 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 June 2021 10:16:00 UTC.

© Publicnow 2021
All news about GALAPAGOS NV
07/15Galapagos ADRs Down After Study Data
07/15SECTOR UPDATE : Health Care Stocks Flat To Lower Pre-Bell Thursday
07/15UPDATE : Galapagos Reports Results From Phase 1b Psoriasis Study -- Shares Slump..
07/15GALAPAGOS : N.V., - Galapagos reports positive topline results with selective TY..
07/15GALAPAGOS : N.V., - Galapagos demonstrates early clinical activity with SIK2/3 i..
07/15GALAPAGOS : Drug Shown Safe In Three Clinical Studies
07/15GALAPAGOS' : Psoriasis Drug Shown Safe, Well-Tolerated in Early-Stage Study
07/14GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in infla..
07/14GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3..
07/14GALAPAGOS : GLPG3667 Shows Positive Results in Psoriasis Patients, Reports Topli..
More news
Sales 2021 484 M 574 M 574 M
Net income 2021 -236 M -280 M -280 M
Net cash 2021 3 238 M 3 842 M 3 842 M
P/E ratio 2021 -15,2x
Yield 2021 -
Capitalization 3 355 M 3 980 M 3 981 M
EV / Sales 2021 0,24x
EV / Sales 2022 0,81x
Nbr of Employees 1 328
Free-Float 73,8%
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 10
Last Close Price 51,21 €
Average target price 73,11 €
Spread / Average Target 42,8%
EPS Revisions
Managers and Directors
Onno van de Stolpe Chief Executive Officer
Bart Filius President & Chief Operating Officer
Raj B. Parekh Chairman
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV-36.37%3 980
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 907